$59.26
0.360.61%
At Close: -
$59.26
00.00%
After Hours: 4:00 PM EDT
15 minutes delayed
Corbus Pharmaceuticals
CRBPNASDAQ
want to know what
the Bulls & Bears Say?
Corbus Pharmaceuticals (NASDAQ:CRBP) Stock, Analyst Ratings, Price Targets, Forecasts
Corbus Pharmaceuticals Holdings Inc has a consensus price target of $59.2 based on the ratings of 5 analysts. The high is $85 issued by B. Riley Securities on June 26, 2024. The low is $3 issued by HC Wainwright & Co. on March 8, 2023. The 3 most-recent analyst ratings were released by Oppenheimer, B. Riley Securities, and RBC Capital on July 10, 2024, June 26, 2024, and June 11, 2024, respectively. With an average price target of $82.33 between Oppenheimer, B. Riley Securities, and RBC Capital, there's an implied 38.94% upside for Corbus Pharmaceuticals Holdings Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Oppenheimer
B. Riley Securities
RBC Capital
Jefferies
HC Wainwright & Co.
1calculated from analyst ratings
Analyst Ratings for Corbus Pharmaceuticals
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 07/10/2024 | Buy Now | 35% | Oppenheimer | Jeff Jones | $80 → $80 | Reiterates | Outperform → Outperform | Get Alert |
| 06/26/2024 | Buy Now | 43.44% | B. Riley Securities | Kalpit Patel | → $85 | Initiates | → Buy | Get Alert |
| 06/11/2024 | Buy Now | 38.37% | RBC Capital | Brian Abrahams | $77 → $82 | Maintains | Outperform | Get Alert |
| 06/03/2024 | Buy Now | 35% | Oppenheimer | Jeff Jones | $60 → $80 | Maintains | Outperform | Get Alert |
| 05/13/2024 | Buy Now | 29.94% | RBC Capital | Brian Abrahams | → $77 | Initiates | → Outperform | Get Alert |
| 05/08/2024 | Buy Now | 1.25% | Oppenheimer | Jeff Jones | $58 → $60 | Maintains | Outperform | Get Alert |
| 03/13/2024 | Buy Now | -2.13% | Oppenheimer | Jeff Jones | $51 → $58 | Reiterates | Outperform → Outperform | Get Alert |
| 03/06/2024 | Buy Now | -22.38% | Jefferies | Maury Raycroft | $4 → $46 | Upgrade | Hold → Buy | Get Alert |
| 01/29/2024 | Buy Now | -13.94% | Oppenheimer | Jeff Jones | $20 → $51 | Maintains | Outperform | Get Alert |
| 08/09/2023 | Buy Now | -62.88% | Oppenheimer | Jeff Jones | → $22 | Reiterates | Outperform → Outperform | Get Alert |
| 05/10/2023 | Buy Now | -62.88% | Oppenheimer | Jeff Jones | → $22 | Upgrade | Perform → Outperform | Get Alert |
| 03/08/2023 | Buy Now | -94.94% | HC Wainwright & Co. | Andrew Fein | → $3 | Reiterates | → Buy | Get Alert |
| 02/14/2023 | Buy Now | -94.94% | HC Wainwright & Co. | Andrew Fein | → $3 | Reiterates | → Buy | Get Alert |
FAQ
What is the target price for Corbus Pharmaceuticals (CRBP) stock?
The latest price target for Corbus Pharmaceuticals (NASDAQ:CRBP) was reported by Oppenheimer on July 10, 2024. The analyst firm set a price target for $80.00 expecting CRBP to rise to within 12 months (a possible 35.00% upside). 10 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Corbus Pharmaceuticals (CRBP)?
The latest analyst rating for Corbus Pharmaceuticals (NASDAQ:CRBP) was provided by Oppenheimer, and Corbus Pharmaceuticals reiterated their outperform rating.
When was the last upgrade for Corbus Pharmaceuticals (CRBP)?
The last upgrade for Corbus Pharmaceuticals Holdings Inc happened on March 6, 2024 when Jefferies raised their price target to $46. Jefferies previously had a hold for Corbus Pharmaceuticals Holdings Inc.
When was the last downgrade for Corbus Pharmaceuticals (CRBP)?
There is no last downgrade for Corbus Pharmaceuticals.
When is the next analyst rating going to be posted or updated for Corbus Pharmaceuticals (CRBP)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Corbus Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Corbus Pharmaceuticals was filed on July 10, 2024 so you should expect the next rating to be made available sometime around July 10, 2025.
Is the Analyst Rating Corbus Pharmaceuticals (CRBP) correct?
While ratings are subjective and will change, the latest Corbus Pharmaceuticals (CRBP) rating was a reiterated with a price target of $80.00 to $80.00. The current price Corbus Pharmaceuticals (CRBP) is trading at is $59.26, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.